Last reviewed · How we verify
Salmonella septicemia — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Rocephin | ceftriaxone | Generic (originally Roche) | Cephalosporin antibiotic (third-generation) | Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A | 1984-12-21 | |
| Unasyn | AMPICILLIN | Bristol-Myers Squibb | Penicillin-class Antibacterial | Transient receptor potential cation channel subfamily M member 4 | 1965-01-01 | |
| Ceftriaxon | Ceftriaxon | Centre Hospitalier Universitaire Vaudois | Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Bristol-Myers Squibb · 1 drug in Salmonella septicemia
- Centre Hospitalier Universitaire Vaudois · 1 drug in Salmonella septicemia
- Generic (originally Roche) · 1 drug in Salmonella septicemia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Salmonella septicemia:
- Salmonella septicemia treatment updates — RSS
- Salmonella septicemia treatment updates — Atom
- Salmonella septicemia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Salmonella septicemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/salmonella-septicemia. Accessed 2026-06-10.
Related
- Salmonella septicemia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing